Matthew ‘Matt’ Wayne Johnson is an Associate Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University. His research is concerned with addiction medicine, drug abuse, and drug dependence.
From his bio: “Matt published psychedelic risk and safety guidelines in 2008, helping to resurrect human psychedelic research. He published the first research on psychedelic treatment of tobacco addiction in 2014, and the largest study of psilocybin in treating cancer distress in 2016.”
Matt Johnson is one of the most active researchers in the psychedelics field at this moment.
And also advises Entheogen Biomedical, Field Trip, Otsuka Pharmaceutical, and Silo Pharma.
Matt is also active on Twitter where he has one of the best biographies you can think of “Professor at Johns Hopkins studying uppers (cocaine, nicotine, meth), downers (alcohol), all-arounders (psychedelics).”
Notable Research Papers
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness (MacLean et al., 2011)
- Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later (Griffiths et al., 2008)
- Human hallucinogen research: guidelines for safety (Johnson et al., 2008)
In our database you will also find him as an author on many more papers.
- Dr. Matthew Johnson Joins AWAKN Life Sciences (press release, September 2020)
- INSIGHT 2019: Therapeutic Effects of Psilocybin (Matthew Johnson) (Insight, 2019)
- Matthew W. Johnson: Psychedelic Research at Johns Hopkins (Colloquium on Psychedelic Psychiatry, 2018)